Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03133650 · ClinicalTrials.gov registry record · Phase 1
A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing
A Phase 1 study of Esophagogastric Cancer and Moderate to Severe Dysphagia, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 3
- Study locations
NCT03133650: Active Phase 1 study of Esophagogastric Cancer and Moderate to Severe Dysphagia, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03133650 is a Phase 1 study of Esophagogastric Cancer and Moderate to Severe Dysphagia that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 12 participants, below the 81-participant average among 5 other Esophagogastric Cancer trials with a reported enrollment target (85% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03133650, a Phase 1 study of Esophagogastric Cancer and Moderate to Severe Dysphagia, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to establish the highest dose of laser light for WST-11 VTP to treat obstruction from esophageal cancer that can be safely given.
Primary Outcome
The maximally tolerated laser light fluence rate (mW/cm) of light exposure for VTP of malignant obstruction due to esophagogastric cancer will be measured by examining 6 fluence rates beginning with a fluence rate of 150 nW/cm, then increasing by 50mW/cm, up to a maximum of 400 mW/cm (150, 200, 250 300, 350, 400).
Conditions Studied
Interventions
- DRUG WST 11-mediated VTP therapy
Study Locations (3)
New York
- Memorial Sloan - Kettering Cancer Center - New York
- Weill Cornell Medical Center (Data Analysis Only) - New York
Other
- Weizmann Institute of Science - Rehovot
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-04-26 |
| Est. Completion | 2026-02-23 |
| Phase | Phase 1 |
What the registry record for NCT03133650 still lists
NCT03133650 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 81-participant average among 5 other Esophagogastric Cancer trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Esophagogastric Cancer appearing as the primary indexed condition, and to 1 intervention - of which WST 11-mediated VTP therapy is the first listed.
NCT03133650 reports a single indexed study location in New York, Other.
Frequently Asked Questions
What is clinical trial NCT03133650 about?
NCT03133650 is a clinical study titled "A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing". The purpose of this study is to establish the highest dose of laser light for WST-11 VTP to treat obstruction from esophageal cancer that can be safely given.
What is the current status of trial NCT03133650?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2017-04-26. Estimated completion is 2026-02-23.
What conditions does trial NCT03133650 study?
This clinical trial studies the following conditions: Esophagogastric Cancer, Moderate to Severe Dysphagia.
What interventions are being tested in trial NCT03133650?
The interventions under investigation include: WST 11-mediated VTP therapy (DRUG).
Who is sponsoring clinical trial NCT03133650?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03133650 being conducted?
This trial has 3 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophagogastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Folfox+Irinotecan+Chemort In Esophageal Cancer
RECRUITING · Phase 2
-
A Study of Amivantamab in People With Esophagogastric Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Tooth Erosion in People With Esophagogastric Cancer
ACTIVE NOT RECRUITING · NA
-
A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI